CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...